Patents Examined by Savitha M Rao
  • Patent number: 11958821
    Abstract: Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: April 16, 2024
    Assignee: Terran Biosciences Inc.
    Inventor: Samuel Clark
  • Patent number: 11951093
    Abstract: Intra-oral formulations comprising soft anticholinergic alkyl esters are useful for treating excessive drooling conditions in subjects, such as humans, suffering from sialorrhea. Preferably, at least one soft anticholinergic ester is provided in an effective amount or concentration in an anhydrous intra-oral formulation that can inhibit excessive drooling resulting from a condition known as sialorrhea.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: April 9, 2024
    Assignee: BODOR LABORATORIES, INC.
    Inventor: Nicholas S. Bodor
  • Patent number: 11944610
    Abstract: Compositions, methods, and uses are contemplated in which a betalain-containing preparation is administered to a mammal to enhance athletic performance. Most preferably, the preparations are substantially nitrate free and acutely and transiently increase hematocrit, erythropoietin, adrenalin, and beta endorphin, while reducing serum lactate, serum lactate dehydrogenase, heart rate and a rate of perceived exertion.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: April 2, 2024
    Assignee: VDF FutureCeuticals, Inc.
    Inventor: Zbigniew Pietrzkowski
  • Patent number: 11945799
    Abstract: The invention provides compounds of formula I, wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds are useful for the treatment or prevention of a variety of conditions, particularly cancer. The invention further provides pharmaceutical compositions comprising the compounds of the invention and uses of the compounds and the compositions.
    Type: Grant
    Filed: March 28, 2023
    Date of Patent: April 2, 2024
    Assignee: IP2IPO INNOVATIONS LIMITED
    Inventors: Gavin Whitlock, Matthew Fuchter
  • Patent number: 11938104
    Abstract: Presented herein are compositions and methods for preventing, reducing, delaying and treating a coronavirus infection and related disorders such as respiratory distress, disseminated intravascular coagulation, and central nervous system pathologies caused by coronavirus infection.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: March 26, 2024
    Assignee: ABREXA PHARMACEUTICALS, INC.
    Inventors: Jesus E. Villafranca, Charles Richard Kissinger
  • Patent number: 11938105
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: March 26, 2024
    Assignee: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • Patent number: 11938126
    Abstract: In some aspects, isomyosmine or a pharmaceutically acceptable salt thereof may be administered to an individual for the treatment of diseases of the visual system.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: March 26, 2024
    Assignee: MyMD Pharmaceuticals, Inc.
    Inventor: Jonnie R. Williams
  • Patent number: 11931365
    Abstract: Described herein is the use sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound.
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: March 19, 2024
    Assignee: RENEO PHARMACEUTICALS, INC.
    Inventors: Niall O′Donnell, Lynn Purkins, Alejandro Dorenbaum
  • Patent number: 11918579
    Abstract: Compositions and methods for the treatment of hair growth and the prevention of hair loss.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: March 5, 2024
    Assignee: Aneira Pharma, Inc.
    Inventor: John Edward Wurst
  • Patent number: 11918555
    Abstract: The disclosure provides compositions and methods of treating diseases and conditions associated with phospholipase D (PLD) toxin. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 5, 2024
    Assignee: NEW FRONTIER LABS, LLC
    Inventors: Robert T. Streeper, Elzbieta Izbicka
  • Patent number: 11911362
    Abstract: Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.
    Type: Grant
    Filed: July 14, 2023
    Date of Patent: February 27, 2024
    Assignee: TULEX PHARMACEUTICALS INC.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala, Romona Bhattacharya
  • Patent number: 11911509
    Abstract: The present invention relates to a pharmaceutical composition comprising a therapeutically effective dose of Lenvatinib mesylate having sodium wherein the weight ratio of Lenvatinib mesylate to sodium carbonates ranges from 1:1.5 to 1:5.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 27, 2024
    Assignee: Synthon B.V.
    Inventors: Luis Nogueiras Nieto, Lisardo Alvarez Fernandez, Jose Velada Calzada, Rohit Kumar
  • Patent number: 11911358
    Abstract: The disclosure provides compositions and methods of inducing an analgesic effect. In particular, the methods include administering to a subject in need a pharmaceutical composition comprising a dicarboxylic acid ester.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: February 27, 2024
    Inventors: Robert T. Streeper, Elzbieta Izbicka
  • Patent number: 11903911
    Abstract: Methods of treating obesity include administering to a subject in need thereof an effective amount of a therapeutic agent capable of reversing an inhibition of a Na/K-ATPase in a small intestine of a subject, such as a basolateral membrane Na/K-ATPase. Administering the therapeutic agent can further decrease an amount of glucose transport and/or decrease an amount of salt absorption in the small intestine of the subject to thereby treat the obesity. Methods for screening for a compound useful for treating obesity include contacting a small intestine cell with an effective amount of a test compound, and detecting whether an activity level of a Na/K-ATPase in the small intestine cell is increased in the presence of the test compound. The test compound is then identified as a compound useful for the treatment of obesity if the activity level of the Na/K-ATPase is increased in the presence of the test compound.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: February 20, 2024
    Assignee: MARSHALL UNIVERSITY RESEARCH CORPORATION
    Inventor: Uma Sundaram
  • Patent number: 11903918
    Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: February 20, 2024
    Assignee: BANNER LIFE SCIENCES LLC
    Inventors: Franck S. F. Rousseau, Thomas Wallace Lategan, Tiffany Nicole Sprague, Jason Michael Vaughn, Justin Roy Hughey
  • Patent number: 11896602
    Abstract: The present invention relates to a method for the management of dysmenorrhea involving administration of an estrogenic component which is preferably selected from the group consisting of estetrol and estetrol-like compounds. Estetrol-like compounds have been surprisingly found to be capable of mitigating dysmenorrhea, either when used alone or in combination with progestogenic components, and this to an extent surpassing the effect obtained with other compositions and with a favourable side-effect profile compared to currently available methods.
    Type: Grant
    Filed: September 30, 2022
    Date of Patent: February 13, 2024
    Assignee: ESTETRA SRL
    Inventors: Maud Jost, Glwadys Rausin
  • Patent number: 11896578
    Abstract: Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, in an amount equivalent to about 1.5 to about 2.5 mg of Compound 1, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, ankylosing spondylitis, biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, hypertensive nephropathy, glomerulosclerosis, myocardial ischemia-reperfusion injury, and acne.
    Type: Grant
    Filed: April 20, 2021
    Date of Patent: February 13, 2024
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Alan Glicklich, Maria Matilde Sanchez Kam, William R. Shanahan
  • Patent number: 11896581
    Abstract: The present disclosure provides compositions and methods for providing a health benefit to an animal utilizing ferulic acid and histidine. For example, a composition can contain ferulic acid and histidine in therapeutically effective amounts for providing the health benefit to the animal.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: February 13, 2024
    Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
    Inventors: Francois-Pierre Martin, Christian Darimont-Nicolau, Andreas Rytz
  • Patent number: 11890269
    Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: February 6, 2024
    Assignee: Research Cancer Institute of America
    Inventor: Mohammed Amin Nezami
  • Patent number: 11884674
    Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: January 30, 2024
    Assignee: BEIGENE SWITZERLAND GMBH
    Inventors: Zhiwei Wang, Yunhang Guo, Gongyin Shi, Lai Wang